ITMI960358A0 - - Google Patents

Info

Publication number
ITMI960358A0
ITMI960358A0 ITMI960358A ITMI960358A ITMI960358A0 IT MI960358 A0 ITMI960358 A0 IT MI960358A0 IT MI960358 A ITMI960358 A IT MI960358A IT MI960358 A ITMI960358 A IT MI960358A IT MI960358 A0 ITMI960358 A0 IT MI960358A0
Authority
IT
Italy
Application number
ITMI960358A
Other languages
Italian (it)
Original Assignee
San Raffaele Centro Fond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by San Raffaele Centro Fond filed Critical San Raffaele Centro Fond
Priority to IT96MI000358A priority Critical patent/IT1282692B1/it
Publication of ITMI960358A0 publication Critical patent/ITMI960358A0/it
Priority to EP97903285A priority patent/EP0885015A2/en
Priority to JP9530545A priority patent/JP2000506835A/ja
Priority to CA002247308A priority patent/CA2247308A1/en
Priority to PCT/EP1997/000704 priority patent/WO1997031655A2/en
Priority to AU17694/97A priority patent/AU1769497A/en
Publication of ITMI960358A1 publication Critical patent/ITMI960358A1/it
Application granted granted Critical
Publication of IT1282692B1 publication Critical patent/IT1282692B1/it

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT96MI000358A 1996-02-27 1996-02-27 Citochine modificate per l'uso in terapia IT1282692B1 (it)

Priority Applications (6)

Application Number Priority Date Filing Date Title
IT96MI000358A IT1282692B1 (it) 1996-02-27 1996-02-27 Citochine modificate per l'uso in terapia
EP97903285A EP0885015A2 (en) 1996-02-27 1997-02-14 Modified cytokines for therapeutic use
JP9530545A JP2000506835A (ja) 1996-02-27 1997-02-14 治療用の修飾サイトカイン
CA002247308A CA2247308A1 (en) 1996-02-27 1997-02-14 Modified cytokines for therapeutic use
PCT/EP1997/000704 WO1997031655A2 (en) 1996-02-27 1997-02-14 Modified cytokines for therapeutic use
AU17694/97A AU1769497A (en) 1996-02-27 1997-02-14 Modified cytokines for therapeutic use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT96MI000358A IT1282692B1 (it) 1996-02-27 1996-02-27 Citochine modificate per l'uso in terapia

Publications (3)

Publication Number Publication Date
ITMI960358A0 true ITMI960358A0 (pt) 1996-02-27
ITMI960358A1 ITMI960358A1 (it) 1997-08-27
IT1282692B1 IT1282692B1 (it) 1998-03-31

Family

ID=11373397

Family Applications (1)

Application Number Title Priority Date Filing Date
IT96MI000358A IT1282692B1 (it) 1996-02-27 1996-02-27 Citochine modificate per l'uso in terapia

Country Status (6)

Country Link
EP (1) EP0885015A2 (pt)
JP (1) JP2000506835A (pt)
AU (1) AU1769497A (pt)
CA (1) CA2247308A1 (pt)
IT (1) IT1282692B1 (pt)
WO (1) WO1997031655A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012554A1 (fr) * 1998-08-28 2000-03-09 Commissariat A L'energie Atomique Procede de synthese d'une chimiokine marquee, chimiokine marquee et trousse d'analyse
FR2783528A1 (fr) * 1998-08-28 2000-03-24 Commissariat Energie Atomique Procede de synthese d'une chimiokine marquee, chimiokine marquee et trousse d'analyse
DE19845798A1 (de) * 1998-09-29 2000-04-13 Schering Ag Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
EP2244738B1 (en) * 2008-01-25 2020-03-04 Gavish-Galilee Bio Applications Ltd Targeting of innate immune response to tumour site
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
KR20160138177A (ko) 2014-03-21 2016-12-02 애브비 인코포레이티드 항-ｅｇｆｒ 항체 및 항체 약물 접합체
CA3027045A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
AU2017277914A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-CD98 antibodies and antibody drug conjugates
CA3027103A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
JP2019526529A (ja) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
US11932694B2 (en) 2017-04-19 2024-03-19 Bluefin Biomedicine, Inc. Anti-VTCN1 antibodies and antibody drug conjugates
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578287A (en) * 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
US5891679A (en) * 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
EP0733066B1 (en) * 1993-12-07 2003-11-19 NeoRx Corporation Pretargeting methods and compounds

Also Published As

Publication number Publication date
WO1997031655A3 (en) 1997-11-13
ITMI960358A1 (it) 1997-08-27
WO1997031655A2 (en) 1997-09-04
IT1282692B1 (it) 1998-03-31
JP2000506835A (ja) 2000-06-06
CA2247308A1 (en) 1997-09-04
AU1769497A (en) 1997-09-16
EP0885015A2 (en) 1998-12-23

Similar Documents

Publication Publication Date Title
AR026661A2 (pt)
BRPI9713914B8 (pt)
ITMI960358A0 (pt)
IN186377B (pt)
BR7600721U (pt)
BR7601346U (pt)
BR9603859A (pt)
IN192622B (pt)
CN3044349S (pt)
CN3045888S (pt)
CN3040367S (pt)
CN3039213S (pt)
CN3040805S (pt)
CN3039060S (pt)
CN3041374S (pt)
CN3041383S (pt)
CN3042289S (pt)
CN3042589S (pt)
CN3043305S (pt)
CN3044168S (pt)
CN3044346S (pt)
CN3044347S (pt)
CN3044348S (pt)
CN3041207S (pt)
CN3045208S (pt)

Legal Events

Date Code Title Description
0001 Granted